Featured Speakers:

• 

  Stephen ClarkeVice President and Head of Drug Metabolism and Pharmacokinetics GlaxoSmithKline

• 

  Tom BaillieDean, School of Pharmacy University of Washington

• 

  Kaushik MitraDirector Merck

• 

  Griff HumphreysExecutive Director Bristol-Myers Squibb

Ensure your candidates enter the clinic with as little risk as possible

With financial stakes of R&D soaring, and idiosyncratic adverse drug reactions becoming the most common cause for drug withdrawal, it has never been more crucial to make the right decisions to reduce the attrition of your pipeline.

The 2^nd Mitigation Strategies for Reactive Metabolites is the only meeting dedicated to helping you implement more effective risk assessment strategies for reactive metabolites in your organization and truly minimize the attrition of your pipeline. 

2^nd Mitigation Strategies for Reactive Metabolites will tap into the latest industry case studies to ensure you are up to date with the latest advances in pharma strategies. Join in discussions with some of the leaders in the field to develop industry consensuses in risk mitigation strategies. 

“Provides an excellent cross-pharma discussion on the issues and strategies for addressing reactive metabolites”
GSK

Hear the most recent developments in the field which are discussed nowhere else and join the discussions to define industry best practice for preclinical risk assessments in drug development. Ensure patient safety in clinical trials and prevent the loss of drug candidates from iADRs.

Not only will companies like Pfizer, Merck, Roche, Bristol-Myers Squibb, GSK and Amgen be sharing their preclinical risk assessment strategies but topics will cover all of the latest advances in this field including:

• Exploring research on immune mediators of drug induced liver injury to avoid drug induced liver toxicity from your candidates
• Establishing the use of toxicogenomics in reactive metabolite research to effectively use data for better decision making
• Using genome-wide approaches to identify genes important in severe adverse drug reactions

Why Attend 2nd Mitigation Strategies for Reactive Metabolites?

With the leaders in the field all in one room, you will leave with the knowledge to:

• Predict and minimize chemical liabilities of new candidates in drug discovery by understanding the successful strategies already put into place by Roche and BMS 
• Avoid bioactivation pathways during discovery an reap the benefits of influencing chemistry early on in development by learning from GSK’s experience of collaborative strategies to change chemistry
• Evaluate your preclinical data to make the right decision about your candidate and assure patient safety by hearing how Biogen Idec interpret evidence of reactive metabolites in various forms 
• Form an effective strategy for your pipeline to address chemically reactive metabolites and avoid attrition from idiosyncratic adverse drug reactions by learning from the latest case studies from Pfizer, Merck and Novartis
• Use Tom Baillie’s expertise to ensure a consensus in risk mitigation strategies for drug candidates subject to metabolic activation to guarantee best practice throughout your company

For more information about what will be covered, please download the brochure now.

This meeting will ensure you are equipped with all the knowledge you need to put effective strategies in place to mitigate against reactive metabolites and prevent the loss of promising candidates from IADRs. 

Who should attend this Reactive Metabolites Industry meeting?

2^nd Mitigation Strategies for Reactive Metabolites is the world’s only annual meeting dedicated to managing the risk of reactive metabolites in drug discovery and development. That means the meeting is for:

• Directors and heads of chemistry, DMPK, biotransformation, in vitro modeling, non-clinical safety and toxicology at large pharmaceutical and biotech companies
• Researchers and scientists dedicated to ensuring patient safety through decreasing the incidence of IADRs
• CEOs and CSOs at biotechs looking to better understand the reactive metabolite field and standardize their toxicology practices
• Providers of platform technologies that are relevant for metabolite screening and characterization as well as optimum toxicity testing 
• Preclinical CROs
• Equipment and reagent suppliers

What next?

1. Download the brochure now to see all the meeting information
2. Stay updated by joining the LinkedIn community. Search "Reactive Metabolites Forum"
3. Something you want to share; white papers or articles? Then let us know... just email any questions to info@hansonwade.com
4. Don't waste time! If you're planning on joining us then get the best rates by securing your place now -  Book online or call +1 212 537 5898